StreetSmart Live! Presents Algernon Pharmaceuticals
Source: Streetwise Reports
October 9, 2020 (Investorideas.com Newswire) Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.
1. The following companies discussed in this broadcast have paid a fee to participate: Algernon Pharmaceuticals.
2. This broadcast does not constitute investment advice. Each viewer is encouraged to consult with his or her individual financial professional and any action a viewer takes as a result of information presented here is his or her own responsibility. This broadcast is not a solicitation for investment. StreetSmart Live does not render general or specific investment advice and the information should not be considered a recommendation to buy or sell any security. StreetSmart Live does not endorse or recommend the business, products, services or securities of any company mentioned here.
3. Statements and opinions expressed are the opinions of the presenters and not of StreetSmart Live or its officers. The presenters are wholly responsible for the validity of the statements. The presenter was not paid by StreetSmart Live for this broadcast. StreetSmart Live requires presenters to disclose any shareholdings in, or economic relationships with, companies that they write about. StreetSmart Live relies upon the authors to accurately provide this information and StreetSmart Live has no means of verifying its accuracy.
4. From time to time, StreetSmart Live and Streetwise Reports and its directors, officers, employees or members of their families, as well as persons interviewed for broadcasts and interviews on the site, may have a long or short position in securities mentioned. As of the date of this broadcast, officers and/or employees of StreetSmart Live and/or Streetwise Reports (including members of their household) own securities of the following companies discussed in this broadcast: Algernon Pharmaceuticals. Algernon Pharmaceuticals has a consulting relationship with StreetSmart (description available at https://www.streetwisereports.com/disclaimer/html#consulting). Algernon Pharmaceuticals is a billboard sponsor of Streetwise Reports, an affiliate of StreetSmart Live (description available at https://www.streetwisereports.com/disclaimer/).
5. Disclosures for Steven Palmer, AlphaNorth Asset Management:
I, or members of my immediate household or family, own securities of the following companies discussed in the broadcast: None
I personally am, or members of my immediate household or family are, paid by the following companies discussed in the broadcast: None
My company has a financial relationship with the following companies discussed in the broadcast: None
Funds controlled by AlphaNorth Asset Management hold shares of the following companies discussed in the broadcast: Algernon Pharmaceuticals
6. Disclosures for Dr. Mark Swaim:
I, or members of my immediate household or family, own securities of the following companies discussed in the broadcast: Algernon Pharmaceuticals
I personally am, or members of my immediate household or family are, paid by the following companies discussed in the broadcast: I am a member of the Medical Scientific Advisory Board of Algernon Pharmaceuticals and so am a paid consultant to Algernon.
My company has a financial relationship with the following companies discussed in the broadcast: BioPub.co itself does not have a relationship with Algernon Pharmaceuticals.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com